Eli Lilly’s shares up as oral GLP-1RA scores in first Phase III trial
Eli Lilly’s Phase III trial with its oral weight loss pill, orforglipron, has met its primary endpoint, reducing A1C levels…
Latest News
-
-
BMS’ Camzyos flops in Phase III non-obstructive hypertrophic cardiomyopathy trial
Bristol Myers Squibb’s (BMS) Phase III trial investigating Camzyos (mavacamten) in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) has failed to…
-
Pfizer drops obesity pill development after liver injury report
Pfizer has terminated the development of its oral obesity candidate danuglipron after a patient on a clinical trial with the…
-
Alzheon’s Alzheimer’s pill fails in Phase III trial
US-based Alzheon’s Alzheimer’s disease pill has failed in a Phase III trial, but the biopharma still holds hope for the…
-
MHRA places UK as global leader of clinical trials once again
The UK Medicines and Healthcare products Regulatory Agency (MHRA) claims the UK is again a global leader in clinical trials.…
-
Rallybio drops drug for rare maternal disorder following Phase II fail
US-based biotech Rallybio is ending its RLYB212 programme for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) following disappointing…
-
UK Government to invest $764m into new health data service
The UK Government has announced a £600m ($764m) funding pot to create a new Health Data Research Service, reducing red…
-
Sarepta and Roche aim to resume paused Elevidys trials following patient death
Sarepta Therapeutics and Roche are looking to get approval to continue clinical trials of their Duchenne muscular dystrophy gene therapy…
-
Lundbeck’s superagonist prompts 61.2% seizure reduction
Lundbeck’s receptor superagonist designed to treat seizures associated with developmental and epileptic encephalopathies (DEEs) has seen a 61.2% reduction in total…
-
Vaxcyte stock sinks despite Phase II IPD vaccine trial success
Vaxcyte’s stock has dropped around 45% despite a Phase II trial of its invasive pneumococcal disease (IPD) vaccine meeting all…
